Connor, Clark & Lunn Investment Management (CC&L)
FOLD

Connor, Clark & Lunn Investment Management (CC&L)’s Amicus Therapeutics FOLD Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Sell
747,465
-470,535
-39% -$6.74M 0.02% 450
2025
Q4 		$17.3M Sell
1,218,000
-801,556
-40% -$7.87M 0.05% 319
2025
Q3 		$15.9M Buy
2,019,556
+180,307
+10% +$1.28M 0.05% 313
2025
Q2 		$10.5M Buy
1,839,249
+1,053,015
+134% +$6.8M 0.04% 386
2025
Q1 		$6.42M Buy
786,234
+483,698
+160% +$4.48M 0.03% 433
2024
Q4 		$2.85M Buy
302,536
+79,602
+36% +$827K 0.01% 634
2024
Q3 		$2.38M Buy
222,934
+75,807
+52% +$826K 0.01% 625
2024
Q2 		$1.46M Buy
+147,127
New +$1.51M 0.01% 749
2024
Q1 		– Sell
-110,665
Closed -$1.57M – 1581
2023
Q4 		$1.57M Buy
110,665
+46,136
+71% +$524K 0.01% 728
2023
Q3 		$785K Buy
64,529
+11,578
+22% +$149K ﹤0.01% 898
2023
Q2 		$665K Buy
52,951
+18,173
+52% +$216K ﹤0.01% 913
2023
Q1 		$386K Buy
+34,778
New +$429K ﹤0.01% 954
2022
Q3 		– Sell
-110,652
Closed -$1.19M – 1156
2022
Q2 		$1.19M Buy
+110,652
New +$911K 0.01% 582
2021
Q1 		– Sell
-107,942
Closed -$2.49M – 1010
2020
Q4 		$2.49M Buy
+107,942
New +$2.21M 0.01% 463
2018
Q2 		– Sell
-11,514
Closed -$173K – 1057
2018
Q1 		$173K Sell
11,514
-144,812
-93% -$2.2M ﹤0.01% 664
2017
Q4 		$2.25M Sell
156,326
-270,263
-63% -$3.71M 0.01% 408
2017
Q3 		$6.43M Buy
426,589
+404,839
+1,861% +$5.36M 0.04% 259
2017
Q2 		$219K Buy
+21,750
New +$175K ﹤0.01% 726
2016
Q1 		– Sell
-129,434
Closed -$1.26M – 857
2015
Q4 		$1.26M Sell
129,434
-253,525
-66% -$2.28M 0.01% 411
2015
Q3 		$5.36M Sell
382,959
-308,975
-45% -$4.85M 0.04% 194
2015
Q2 		$9.79M Sell
691,934
-144,675
-17% -$1.74M 0.09% 110
2015
Q1 		$9.1M Buy
836,609
+310,700
+59% +$2.74M 0.08% 118
2014
Q4 		$4.38M Buy
525,909
+389,309
+285% +$2.67M 0.04% 168
2014
Q3 		$813K Buy
+136,600
New +$716K 0.01% 333
2014
Q2 		– Sell
-14,624
Closed -$33K – 567
2014
Q1 		$33K Sell
14,624
-13,176
-47% -$32.9K ﹤0.01% 665
2013
Q4 		$69K Buy
27,800
+8,700
+46% +$19.1K ﹤0.01% 709
2013
Q3 		$46K Buy
+19,100
New +$47.9K ﹤0.01% 507

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s FOLD Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Amicus Therapeutics (FOLD) stake by 39% in Q1 2026, selling an estimated $6.74M and leaving 747,465 shares worth $10.8M. The position accounts for 0.02% of the portfolio, ranked #450.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in FOLD in Q3 2013 and has held it in 27 quarters since. The position peaked at $17.3M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 747,465 shares of Amicus Therapeutics worth $10.8M as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 470,535 Amicus Therapeutics shares in Q1 2026, an estimated $6.74M.
  • Amicus Therapeutics made up 0.02% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #450 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Amicus Therapeutics in Q3 2013 and has held it in 27 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Amicus Therapeutics position peaked at $17.3M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.